MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
HZNP - Horizon Therapeutics Plc
$90.91
0.34(0.38%)9:00:00 PM 2/26/2021
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing of medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of rheumatoid arthritis (RA), polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company also offers PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis (OA) of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; and VIMOVO for the relief of signs and symptoms of OA, RA, and ankylosing spondylitis to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Summary:

  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
  • MACD is crossing MACD signal line at 0.1. MACD crossing signal line is bullish signal.
Stock Statistics
MarketCap20.1B
PE Ratio50.2
PEG Ratio0.7
P/B5.0
P/S (ttm)10.3
Earning Growth (QoQ)1506%
Revenue Growth (QoQ)
Short %3%
Held by Institutions %91%
1 Day Vol Adjusted Return0.1
1 Month Vol Adjusted Return5.8
3 Month Vol Adjusted Return9.0
6 Month Vol Adjusted Return6.9
20 Days SMA Price ZScore0.9
50 Days SMA Price ZScore1.6
12 -26 Days PPO3.7
1 Month Average Short Volume Ratio46.8
1 Day Volume Change ZScore0.1
1 Month Daily Vol4.6
Related Topics
leak data

Related Topics

Peers

Stock news